UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2018

 

 

OMEROS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Washington		001-34475		91-1663741
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
201 Elliott Avenue West Seattle, WA				98119
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-5000

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On October 4, 2018, Omeros Corporation (the “Company”) received an order from the U.S. Securities and Exchange Commission (the “SEC”) extending a prior grant of confidential treatment. The order resulted from a routine request to extend a previous grant of confidential treatment that was soon to expire for certain information contained in two exhibits that were originally filed in connection with the Company’s 2009 initial public offering. The SEC originally granted confidential treatment for this information on October 7, 2009 and subsequently extended the period of confidential treatment approximately every three years in orders dated September 16, 2012 and September 3, 2015. The applicable exhibits are incorporated by reference to this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number
10.1		Exclusive License and Sponsored Research Agreement between Omeros Corporation and Medical Research Council dated October  31, 2005 (incorporated by reference to Exhibit 10.31 to Amendment No. 5 to the Company’s Registration Statement on Form S-1 (File No.  333-148572) filed with the SEC on September 16, 2009).
10.2		Amendment dated May  8, 2007 to Exclusive License and Sponsored Research Agreement between Omeros Corporation and the Medical Research Council dated October 31, 2005 (incorporated by reference to Exhibit 10.32 to the Company’s Registration Statement on Form S-1 (File No. 333-148572) filed with the SEC on January 9, 2008).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				OMEROS CORPORATION
Date: October 5, 2018				By:		/s/ Gregory A. Demopulos
						Gregory A. Demopulos, M.D.
						President, Chief Executive Officer and
						Chairman of the Board of Directors